Newsweek spoke to some experts about whether the weight loss drug could have an impact on birth rates in America.

Omada Health (OMDA) is a strong buy. Backed by 29 studies, key partnerships with Cigna and CVS drive growth, credibility, and ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

The rise of GLP-1 drugs is a reminder that we must move beyond the simple equation of thinness as health and value. These ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Driven by expensive drugs, hospital stays and growing behavioral health needs, healthcare spending is expected to keep rising ...

The United States officially won't be involved in an enhanced pandemic global response enacted by the World Health ...

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Madison Malone, SunStop food and brand manager, says traditional healthy offerings have declined in sales—and the c-store ...

In a new study, one nutrient made a difference in muscle loss for people losing weight on drugs like Ozempic. Here's what to eat to preserve your muscle on the meds.

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...